

12 February 2026

**ASX Announcement**

## **Contained fired event at R&D facility – fully insured and indemnity granted**

PolyNovo Limited (**PolyNovo** or the **Company**) previously announced on 4 November 2025 that a fire occurred at the Company's new standalone R&D facility, which was quickly contained by the fire brigade. The building was unoccupied at the time, and no one was injured.

Despite the fire affecting only a small section of the facility, following specialist investigation, the resultant smoke damage has rendered the significant majority of the R&D equipment, including the specialised HVAC system, unusable. The R&D facility office (located in the same building) remains unaffected and will be made available once cleaning is completed and facilities restored.


Importantly, we can confirm that all R&D activities have continued without interruption in the original laboratory, located in a separate facility.

The cost to rebuild and restore the R&D facility to its previous state is fully covered by insurance, and the Company's insurers have provided written notice of indemnity. The book value of assets written off as a result of the fire totals A\$4.4m, which will be recorded in the 1H26 financial statements. An estimate of insurance proceeds of A\$4.6m will also be included in Other Income in the 1H26 financial statements. We expect the claim to be finalised by 30 June 2026, with any further amounts expected to be recovered to be recognised in 2H26.

The rebuilding of the facility is expected to be completed by September 2026.

As previously noted, this event will not impact the Company's manufacturing capacity, inventory or sales.

This announcement has been authorised by PolyNovo Company Secretary, Jan Gielen.



### About PolyNovo®

**PolyNovo (ASX: PNV) is a leading medical technology company transforming the management of complex wounds.** Headquartered in Melbourne, Australia, it has international operations in the United States, United Kingdom, India, Hong Kong and Singapore and several other markets supported by distributor partners.

The proprietary NovoSorb® polymer is addressing significant unmet needs in wound care, as evidenced by its clinical adoption and patient outcomes, and the Company is leveraging the technology platform to develop new products and markets.

Achievements to date, including continued revenue growth, profitability, numerous clearances and registrations, as well as market leadership in several geographies, provide a strong foundation for continued growth.

For more information see [polynovo.com](https://polynovo.com)

### About NovoSorb® Technology

**NovoSorb® is a proprietary biodegradable polymer platform designed to support tissue regeneration in complex wound care.** The unique characteristics of NovoSorb® provide several key advantages including excellent biocompatibility, control over physical properties, a programmable bio-resorption profile and can be produced in many formats including film, fibre, foam, and coatings.

**NovoSorb® BTM** is a synthetic dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. This innovative product was the first to be commercially available utilising NovoSorb® technology and is supported by a growing body of independent clinical evidence.

**NovoSorb® MTX** is PolyNovo's latest advanced wound care product; a fully synthetic dermal matrix, developed in response to surgeon demand for a dermal substitute without a temporising, sealing membrane. Since receiving FDA 510(k) clearance in 2022, NovoSorb® MTX has rapidly gained surgeon adoption and is emerging as a key driver of growth.